T. Rowe Price Associates’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-142,888
| Closed | -$10.3M | – | 3184 |
|
|
2025
Q4 | $10.3M | Sell |
142,888
-9,644,529
| -99% | -$623M | ﹤0.01% | 1228 |
|
|
2025
Q3 | $426M | Sell |
9,787,417
-1,021,310
| -9% | -$41.3M | 0.05% | 302 |
|
|
2025
Q2 | $307M | Sell |
10,808,727
-529,371
| -5% | -$15.8M | 0.03% | 346 |
|
|
2025
Q1 | $335M | Buy |
11,338,098
+295,275
| +3% | +$9.2M | 0.04% | 325 |
|
|
2024
Q4 | $321M | Buy |
11,042,823
+408,861
| +4% | +$17.1M | 0.04% | 340 |
|
|
2024
Q3 | $488M | Sell |
10,633,962
-282,664
| -3% | -$12.3M | 0.06% | 281 |
|
|
2024
Q2 | $446M | Buy |
10,916,626
+3,487,519
| +47% | +$100M | 0.05% | 292 |
|
|
2024
Q1 | $190M | Buy |
7,429,107
+516,446
| +7% | +$8.09M | 0.02% | 427 |
|
|
2023
Q4 | $62.6M | Buy |
6,912,661
+296,238
| +4% | +$1.98M | 0.01% | 640 |
|
|
2023
Q3 | $42.2M | Sell |
6,616,423
-67,818
| -1% | -$584K | 0.01% | 740 |
|
|
2023
Q2 | $74.1M | Sell |
6,684,241
-180,144
| -3% | -$2.26M | 0.01% | 595 |
|
|
2023
Q1 | $105M | Buy |
6,864,385
+157,098
| +2% | +$3.46M | 0.02% | 501 |
|
|
2022
Q4 | $149M | Buy |
6,707,287
+1,538,264
| +30% | +$22.9M | 0.02% | 430 |
|
|
2022
Q3 | $84.4M | Sell |
5,169,023
-2,714,102
| -34% | -$51.9M | 0.01% | 518 |
|
|
2022
Q2 | $115M | Sell |
7,883,125
-102,410
| -1% | -$1.52M | 0.01% | 623 |
|
|
2022
Q1 | $147M | Buy |
7,985,535
+253,689
| +3% | +$4.31M | 0.01% | 621 |
|
|
2021
Q4 | $184M | Buy |
7,731,846
+641,196
| +9% | +$15.3M | 0.02% | 580 |
|
|
2021
Q3 | $175M | Buy |
7,090,650
+4,553,579
| +179% | +$99M | 0.02% | 583 |
|
|
2021
Q2 | $62.7M | Buy |
2,537,071
+779,336
| +44% | +$18.1M | 0.01% | 952 |
|
|
2021
Q1 | $38.3M | Buy |
1,757,735
+812,897
| +86% | +$19.9M | ﹤0.01% | 1097 |
|
|
2020
Q4 | $24.1M | Sell |
944,838
-12,813
| -1% | -$374K | ﹤0.01% | 1176 |
|
|
2020
Q3 | $27M | Buy |
957,651
+7,251
| +0.8% | +$210K | ﹤0.01% | 1071 |
|
|
2020
Q2 | $26.9M | Buy |
+950,400
| New | +$27.4M | ﹤0.01% | 1050 |
|
Other funds holding RNAM
T. Rowe Price Associates's RNAM Position: Q1 2026 in Review
T. Rowe Price Associates sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 142,888 shares — an estimated $10.3M sold.
T. Rowe Price Associates first reported a position in RNAM in Q2 2020 and held it in 23 quarters. The position peaked at $488M in Q3 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- T. Rowe Price Associates reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- T. Rowe Price Associates sold 142,888 Avidity Biosciences shares in Q1 2026, an estimated $10.3M.
- T. Rowe Price Associates first reported a position in Avidity Biosciences in Q2 2020 and held it in 23 quarters.
- T. Rowe Price Associates's Avidity Biosciences position peaked at $488M in Q3 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.